Genzyme Sees Renagel Clinical Data Driving Sales After Purchase Of GelTex

Renagel sales growth will be driven by results from cardiac calcification and morbidity and mortality trials, Genzyme Chairman Henri Termeer indicated during a Sept. 11 conference call announcing Genzyme's $1 bil. acquisition of GelTex.